title: Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction.
abstract: Reperfusion may limit the amount of potentially salvageable myocardium through the introduction of cellular elements into previously ischemic but viable myocardium (reperfusion injury). It has been demonstrated that intracoronary infusion of a 20% intravascular perfluorochemical emulsion (Fluosol) significantly reduces infarct size and results in improved left ventricular function in the canine model. This pilot study was performed to explore the existence of myocardial reperfusion injury in humans. Utilizing Fluosol as a probe in conjunction with emergency coronary angioplasty, 26 patients presenting within 4 h with a first anterior myocardial infarction were randomized to emergency angioplasty or angioplasty followed by a 30-min intracoronary infusion of Fluosol at 40 ml/min. Global and regional ventricular function were assessed immediately and a mean of 12 days after successful angioplasty with contrast ventriculography. Infarct size was semiquantitated with thallium-201 single-photon emission computed tomography (SPECT) images before discharge. Twelve patients (six undergoing angioplasty alone, six treated with angioplasty and Fluosol) had an occluded infarct-related vessel (Thrombolysis in Myocardial Infarction [TIMI] grade 0 to 1) at the time of emergency catheterization and were included in the final analysis. At 12 days after successful angioplasty, the improvement in regional ventricular function was greater in patients receiving adjunctive therapy with intracoronary Fluosol versus those undergoing angioplasty alone utilizing both the radial shortening and centerline method, respectively (23 +/- 3.1% vs. 8 +/- 2.3%, p less than 0.02; and -1.6 +/- 0.4 vs. -2.9 +/- 0.2 SD/chord, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
authors.forename: M B
authors.initials: MB
authors.lastname: Forman
authors.forename: J M
authors.initials: JM
authors.lastname: Perry
authors.forename: B H
authors.initials: BH
authors.lastname: Wilson
authors.forename: M S
authors.initials: MS
authors.lastname: Verani
authors.forename: P R
authors.initials: PR
authors.lastname: Kaplan
authors.forename: F A
authors.initials: FA
authors.lastname: Shawl
authors.forename: G C
authors.initials: GC
authors.lastname: Friesinger
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001802:Blood Substitutes / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D004630:Emergencies; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000175:diagnosis / Q000453:epidemiology*; D010865:Pilot Projects; D011877:Radionuclide Imaging; D016276:Ventricular Function / Q000502:physiology
chemical_list: D001802:Blood Substitutes; D005466:Fluorocarbons; C050455:fluosol